Affordable Access

Access to the full text

Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant

Authors
  • Kim, Kunhwa1
  • Jabbour, Elias1
  • Short, Nicholas J.1
  • Kebriaei, Partow1
  • Kantarjian, Hagop1
  • Ravandi, Farhad1
  • 1 The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA , Houston (United States)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
Jun 14, 2021
Volume
23
Issue
8
Identifiers
DOI: 10.1007/s11912-021-01086-y
Source
Springer Nature
Keywords
Disciplines
  • Topical Collection on Pediatric Oncology
License
Yellow

Abstract

Purpose of ReviewOver the past two decades, tyrosine kinase inhibitors (TKIs) have changed the management of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), and this has led to significant improvement in their outcome. In this review, we will provide an overview of the current understanding of treatment of Ph+ ALL focusing on TKIs, alloHSCT, and novel therapies.Recent findingsThe advent of more potent TKIs and the novel therapeutic options including blinatumomab, inotuzumab ozogamicin, and CD19 CAR-T therapy has changed the role of allogeneic hematopoietic stem cell transplant (alloHSCT) and intensive chemotherapy. To avoid toxicity from the historical treatment strategies, a more individualized, targeted approach to therapy including detection and monitoring of measurable residual disease (MRD) has become of interest.SummaryThe treatment of patients with Ph+ ALL has been rapidly evolving with a more individualized, targeted treatment and use of TKIs and novel therapy.

Report this publication

Statistics

Seen <100 times